Earnings ·
Nkarta reports Q3 net loss of $33.3M and cash balance of $216.0M
NKTXNkarta, Inc.
Nkarta, Inc. reported a third-quarter 2026 net loss of $33.3 million, or $0.45 per share, compared to a loss of $21.7 million in the prior-year period. Research and development expenses increased to $29.5 million from $20.2 million, while general and administrative expenses decreased slightly to $6.3 million. The company ended the quarter with $216.0 million in cash, cash equivalents, restricted cash, and investments, which management expects will fund operations into 2029. Nkarta also announced that initial clinical data for its lead candidate NKX019 in myositis and systemic sclerosis will be presented at ACR Convergence 2026. The company is a clinical-stage biotechnology firm developing engineered natural killer cell therapies to treat autoimmune diseases.